GENFIT (XUP.DE) Stock Fundamental Analysis

FRA:XUP • FR0004163111

5.26 EUR
+0.05 (+1.06%)
Last: Jan 22, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

Overall XUP gets a fundamental rating of 2 out of 10. We evaluated XUP against 77 industry peers in the Biotechnology industry. XUP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XUP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year XUP has reported negative net income.
  • XUP had a negative operating cash flow in the past year.
  • In multiple years XUP reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: XUP reported negative operating cash flow in multiple years.
XUP.DE Yearly Net Income VS EBIT VS OCF VS FCFXUP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

  • XUP has a Return On Assets (-17.98%) which is comparable to the rest of the industry.
  • XUP has a Return On Equity of -74.24%. This is comparable to the rest of the industry: XUP outperforms 57.65% of its industry peers.
Industry RankSector Rank
ROA -17.98%
ROE -74.24%
ROIC N/A
ROA(3y)-8.88%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XUP.DE Yearly ROA, ROE, ROICXUP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • XUP's Profit Margin has declined in the last couple of years.
  • XUP's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 95.42%, XUP belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
  • In the last couple of years the Gross Margin of XUP has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for XUP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.42%
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
XUP.DE Yearly Profit, Operating, Gross MarginsXUP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • XUP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • XUP has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for XUP has been increased compared to 5 years ago.
  • The debt/assets ratio for XUP is higher compared to a year ago.
XUP.DE Yearly Shares OutstandingXUP.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XUP.DE Yearly Total Debt VS Total AssetsXUP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -1.21, we must say that XUP is in the distress zone and has some risk of bankruptcy.
  • XUP's Altman-Z score of -1.21 is on the low side compared to the rest of the industry. XUP is outperformed by 62.35% of its industry peers.
  • A Debt/Equity ratio of 0.10 indicates that XUP is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.10, XUP is doing good in the industry, outperforming 62.35% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -1.21
ROIC/WACCN/A
WACC7.37%
XUP.DE Yearly LT Debt VS Equity VS FCFXUP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 3.74 indicates that XUP has no problem at all paying its short term obligations.
  • XUP's Current ratio of 3.74 is fine compared to the rest of the industry. XUP outperforms 70.59% of its industry peers.
  • A Quick Ratio of 3.74 indicates that XUP has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 3.74, XUP is doing good in the industry, outperforming 77.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.74
Quick Ratio 3.74
XUP.DE Yearly Current Assets VS Current LiabilitesXUP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for XUP have decreased strongly by -289.19% in the last year.
  • Measured over the past years, XUP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -70.77% on average per year.
  • The Revenue for XUP has decreased by -45.94% in the past year. This is quite bad
  • The Revenue has been growing by 11.61% on average over the past years. This is quite good.
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-45.28%

3.2 Future

  • Based on estimates for the next years, XUP will show a very negative growth in Earnings Per Share. The EPS will decrease by -29.44% on average per year.
  • XUP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.87% yearly.
EPS Next Y-229.07%
EPS Next 2Y-97.6%
EPS Next 3Y-36.76%
EPS Next 5Y-29.44%
Revenue Next Year-34.41%
Revenue Next 2Y-21.78%
Revenue Next 3Y-8%
Revenue Next 5Y-1.87%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XUP.DE Yearly Revenue VS EstimatesXUP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
XUP.DE Yearly EPS VS EstimatesXUP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • XUP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year XUP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XUP.DE Price Earnings VS Forward Price EarningsXUP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XUP.DE Per share dataXUP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • A cheap valuation may be justified as XUP's earnings are expected to decrease with -36.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-97.6%
EPS Next 3Y-36.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • XUP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GENFIT

FRA:XUP (1/22/2026, 7:00:00 PM)

5.26

+0.05 (+1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20
Earnings (Next)02-26
Inst Owners6.03%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap263.02M
Revenue(TTM)45.41M
Net Income(TTM)-38.96M
Analysts90
Price Target9.17 (74.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.57%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-39.31%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.79
P/FCF N/A
P/OCF N/A
P/B 5.01
P/tB 123.71
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.91
BVpS1.05
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.98%
ROE -74.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.42%
FCFM N/A
ROA(3y)-8.88%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 188.34%
Cap/Sales 7.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.74
Quick Ratio 3.74
Altman-Z -1.21
F-Score2
WACC7.37%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
EPS Next Y-229.07%
EPS Next 2Y-97.6%
EPS Next 3Y-36.76%
EPS Next 5Y-29.44%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-45.28%
Revenue Next Year-34.41%
Revenue Next 2Y-21.78%
Revenue Next 3Y-8%
Revenue Next 5Y-1.87%
EBIT growth 1Y-217.08%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year-89.66%
EBIT Next 3Y-36.71%
EBIT Next 5YN/A
FCF growth 1Y87.75%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y93.86%
OCF growth 3Y-46.21%
OCF growth 5YN/A

GENFIT / XUP.DE FAQ

What is the fundamental rating for XUP stock?

ChartMill assigns a fundamental rating of 2 / 10 to XUP.DE.


What is the valuation status of GENFIT (XUP.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to GENFIT (XUP.DE). This can be considered as Overvalued.


How profitable is GENFIT (XUP.DE) stock?

GENFIT (XUP.DE) has a profitability rating of 2 / 10.


What is the expected EPS growth for GENFIT (XUP.DE) stock?

The Earnings per Share (EPS) of GENFIT (XUP.DE) is expected to decline by -229.07% in the next year.